Marina Biotech Publishes Pre-Clinical Research on the Application of DiLA2 Delivery Technology for Systemic Delivery of siRNAs

Research Published in Molecular Therapy Demonstrates Knockdown of Multiple Liver Targets With DiLA2-Based Formulations

| Source: Marina Biotech, Inc. Marina Biotech, Inc.

BOTHELL, WA--(Marketwire - Apr 26, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today the publication of data highlighting the application of their proprietary DiLA2-based delivery technology for systemic administration of siRNAs; this work is described in Molecular Therapy -- a Nature publication. The manuscript, titled "An Amino Acid-based Amphoteric Liposomal Delivery System for Systemic Administration of siRNA" (Adami et al. Molecular Therapy advance online publication 19 April 2011 doi: 10.1038/mt.2011.56;